FDA approves new drug rare form ALS ABC News ABC NewsVideoLiveShowsClimateInterest Successfully AddedWell notify news aboutTurn desktop notifications breaking stories interest OffOnStream onFDA approves new drug rare form ALSAbout 2 ALS patients mutation drug targetsBySony Salzman Mary KekatosApril 25 2023 455 PM132Signage seen outside Food Drug Administration headquarters White Oak Maryland Aug 29 2020Andrew KellyReutersThe US Food Drug Administration approved new drug Tuesday treat rare form amyotrophic lateral sclerosis ALSThe drug Qalsody tofersen expected help people specific mutation SOD1 applies 2 ALS populationIn statement FDA said estimates fewer 500 patients SOD1ALS United StatesMORE House investigation finds FDA drug firm Biogen ignored internal concerns Alzheimers drugAmong qualify drug potential slow muscle degeneration targeting SOD1 messenger RNA mRNA genetic material tells body make proteins reduce protein madeStudies showed drug reduced plasma neurofilament light NfL bloodbased biomarker axonal nerve injury neurodegeneration according FDAPatients receiving Qalsody nominally significant reductions plasma NfL concentration Week 28 compared placebo arm FDA said statementBiogens drug Qalsody approved FDA rare form Lou Gehrigs disease April 25 2023 though requiring research confirm truly helps patientsBiogen via APThe genetic form ALS caused mutation SOD1 one aggressive forms disease affects person experiencing disease half members family Dr James Berry chief division ALS motor neuron diseases Massachusetts General Hospital told ABC NewsThe gene first discovered hospital 1990s ALS patients MGH currently receiving drug part trialThis really brings hope finally changing paradigm treat people ALS disease course looks like incredibly exciting Berry saidThe drug given via lumbar puncture spinal injection three doses 14day intervals followed monthly dosingResearchers determined Qalsody safe common side effects pain fatigue joint muscle pain increased white blood cells cerebrospinal fluidThe drug given conditional approval FDA fast track designation Biogen makes drug still need complete additional larger studies effectivenessI dont really doubts theres efficacy Dr Colin Quinn neurologist Penn Medicine wasnt involved trial told ABC News Theyve continued collect data open label extension quite encouragingMORE Wisdom Morrie New insights 30 years former professors deathAlthough drug subset ALS patents Quinn others hope pave way treatments patients sporadic ALS meaning comes suddenly rather due genetic mutationTreatments silence RNA dont want potential broad application ALS said fact multiple trials looking thing proving approach works think really importantIt comes FDA approved another drug Biogen Aduhelm 2021 treat Alzheimers disease despite lack evidence effectiveALS also sometimes known Lou Gehrigs disease neurodegenerative disease affects nerve cells brain leading weakness paralysisThe disease often begins patients experiencing muscle twitching weakness one arm leg followed difficulty swallowing slurring speechSignage seen outside Food Drug Administration headquarters White Oak Maryland Aug 29 2020Andrew KellyReutersPatients conditions eventually decline point unable move speak eat even breathe ownAccording 2017 estimate Centers Disease Control Prevention 32000 people US live ALSThere cure already approved treatments may help always fatal according ALS AssociationALS many years ago considered disease really would hard time making headway Berry said effective therapy thats approved people SOD1 ALS really changing way care people clinical trials amazing timeTop StoriesSheriff Uber Eats driver slain dismembered making deliveryApr 25 306 PMFarmers rally first ladys comments banning dog meatApr 25 658 AMAuthorities find 8 bodies Mexican resort Cancun4 hours agoNeurosurgeon found shot dead home wellbeing checkApr 25 347 PMWoman pleads guilty Floridas 1990 killer clown caseApr 25 530 PMABC News Live247 coverage breaking news live eventsABC News NetworkPrivacy PolicyYour US State Privacy RightsChildrens Online Privacy PolicyInterestBased AdsAbout Nielsen MeasurementTerms UseDo Sell Share Personal InformationContact UsCopyright Â© 2023 ABC News Internet Ventures rights reserved